Patients with immune thrombocytopenic purpura (ITP) rarely suffer life-threatening haemorrhages despite significant thrombocytopenia, probably because large numbers of hyperfunctioning platelets are present. Thrombospondin is a platelet a-granule protein and its plasma level may reflect platelet activation. We assessed circulating thrombospondin levels in 12 newly diagnosed ITP patients (one man; 11 women, aged 36 ± 16 years) before they were treated for ITP. Twelve healthy people (four men; eight women, aged 31 ± 11 years) acted as controls. Plasma thrombospondin concentrations were measured using enzyme-linked immunoassays. Thrombospondin concentrations tended to be higher, despite thrombocytopenia, in ITP patients (158.8 ± 28.2 ng/ml) compared with controls (120.7 ± 18.2 ng/ml). The difference was not statistically significant, but the relatively high circulating thrombospondin concentrations we observed suggest that residual platelets could be activated in ITP, thus indicating a more benign clinical course compared with aplastic thrombocytopenia.
Introduction
Immune (idiopathic) thrombocytopenic purpura (ITP) is an autoimmune disorder, characterized by auto-antibody-mediated platelet destruction which results in thrombocytopenia.
Both platelet destruction and inhibition of thrombopoiesis may be important in the pathogenesis of ITP, 1 which is generally considered to be a benign disease. Thrombocytopenia can be severe but few ITP patients suffer severe haemorrhage, 2, 3 which may be attributed to more active residual platelets in ITP patients. 4 Thrombospondin is a secreted trimeric glycoprotein that affects cell growth, adhesion and migration. The complex biological activity of thrombospondin is ascribed to its ability to bind to cell-surface receptors, growth factors and extracellular-matrix proteins. 5 Like other platelet a-granule proteins (e.g. fibrinogen, albumin and von Willebrand factor) thrombospondin is synthesized in newly formed circulating platelets. 6 A high percentage of young, activated, compound platelets is present in peripheral blood taken from ITP patients and, like P-selectin, plasma thrombospondin levels may reflect platelet activation in patients with thrombocytopenia. 4, 7, 8 In the present study, plasma concentrations of thrombospondin were investigated at the initial clinical presentation of ITP, to establish whether this adhesive molecule is a marker of OI . Özcebe, S Karakuş, I . C Haznedaroglu et al. Plasma thrombospondin in immune thrombocytopenic purpura platelet activation 9 during the pathobiology of the disease.
Patients and methods

PATIENTS
Twelve patients (one man, 11 women; mean age 36 ± 16 years; range, 18 -76 years) with newly diagnosed ITP were included in this cross-sectional study. Blood samples were obtained from patients at diagnosis, before any ITP treatment was initiated. Platelet counts in two ITP patients ranged between 10 000/mm 3 and 20 000/mm 3 but counts in all other patients were below 10 000/mm 3 . Twelve healthy adult subjects (four men, eight women; mean age 31 ± 11 years; range, 18 -55 years) served as the control group.
BLOOD SAMPLING AND ASSAYS
Venous blood samples were drawn from all subjects into 3.8% trisodium citrate without venous occlusion to determine plasma thrombospondin levels. Plasma was obtained by immediate centrifugation of the samples for 20 min at 3000 g and then stored at -70 ºC until assayed. Thrombospondin was assayed by sandwich type enzyme-linked immunoassay (ELISA; Asserachrom™ Thrombospondine, Diagnostica Stago, France). Each sample was studied in duplicate.
STATISTICAL ANALYSIS
The Mann-Whitney U-test was used to compare plasma thrombospondin levels in patients and controls. Results were expressed as mean ± SD. Statistical significance was assigned to P-values < 0.05.
Results
Demographic and laboratory characteristics of patients and control groups are shown in Table 1 . The mean plasma thrombospondin concentration was 158.8 ± 28.2 ng/ml (range, 95 -195 ng/ml) in patients with ITP and 120.7 ± 18.2 ng/ml (range, 28 -212 ng/ml) in the control group. The higher thrombospondin levels in ITP patients did not reach statistical significance.
Discussion
It has been suggested that residual platelets are activated in ITP, 4 which is a condition that has a relatively benign clinical course compared with other thrombocytopenias. Levels of other a-granule proteins, which are also known to reflect platelet activity, have been reported to be elevated in ITP patients, 4, 7 which is consistent with our observation. Generally, however, ITP patients do not experience life-threatening haemorrhages, despite having severe thrombocytopenia. 2, 3 Augmented residual platelet function in ITP patients has been explained by high interleukin 6 (IL-6) and Pselectin concentrations during thrombocytopenia. 4, 7, 10 We have also found significantly (P < 0.01) lower than normal plasma thrombospondin concentrations in thrombocytopenia secondary to acute leukaemias. 8 All ITP patients in the present study had increased bone-marrow megakaryocytes and, even though they were thrombocytopenic, their pretreatment plasma thrombospondin concentrations tended to be raised. This implies that circulating thrombospondin is relatively higher in ITP patients with thrombocytopenia who have increased bone-marrow megakaryocytes, compared with thrombocytopenias associated with megakaryocyte deficiency. Thrombospondin has been considered a marker for platelet activation. 9 This glycoprotein regulates the multimeric size (and therefore haemostatic activity) of von Willebrand factor, a multimeric protein that mediates platelet adhesion to sites of vascular injury. 11 Immune thrombocytopenic purpura is a heterogenous disorder in which platelet count and function can vary greatly between patients.
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. Özcebe, S Karakuş, I . C Haznedaroglu et al. There are many unknown factors in the pathogenesis of ITP: immune platelet destruction and reactive megakaryocytopoiesis are key characteristics of this disease, but there are indications that abnormal megakaryocytopoiesis and ineffective thrombopoiesis may also be significant. 1, 12 In addition, thrombospondin is synthesized in newly formed circulating platelets, which could reflect its role in platelet activation. 6, 9 The role of thrombospondin, and the effects of ITP treatment on thrombospondin levels during the biological and clinical course of the disease should be investigated further. 
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